| Serial Number | 98975225 |
| Word Mark | DAY ONE BIOPHARMACEUTICALS |
| Filing Date | Thursday, September 21, 2023 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Friday, January 10, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Educational services, namely, providing online newsletters in the field of prescription drug information via emails, non-downloadable webinars, and online non-downloadable videos in the field of prescription drug information; educational services, namely, providing prescription drug dosage training; educational services, namely, providing online non-downloadable videos in the field of treatment and diagnosis of tumors and cancer; educational services, namely, providing online non-downloadable videos in the field of treatment and diagnosis of pediatric low-grade glioma; educational services, namely, providing online non-downloadable videos for healthcare service providers, caregivers, and patients in the field of tumors and cancer; educational services, namely, providing online non-downloadable videos for healthcare service providers, caregivers, and patients in the field of pediatric low-grade glioma; providing information regarding tumors and cancer, and pediatric low-grade glioma |
| Description of Mark | The mark consists of the words DAY ONE above the word BIOPHARMACEUTICALS with sun rays emanating from and above the "e" at the end of the word ONE. |
| Goods and Services | Pharmaceutical preparations for human use for treating cancer and oncological diseases; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders |
| Goods and Services | Healthcare insurance administration services; healthcare insurance administration services, namely, providing benefit verification, authorization and re-authorization support, appeals support, and information regarding benefit updates; providing information about healthcare insurance plans; financial services, namely, assessing sources of and facilitating access by patients and their families to financial support from copay support, patient assistance programs (PAP), patient foundations and organizations; financial services, namely, administration of patient reimbursement programs |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| NOT AVAILABLE | BIOPHARMACEUTICALS |
| Goods and Services | Research, development, and product evaluation of pharmaceutical preparations for the prevention and treatment of cancer; research laboratory analysis and research of drugs and pharmaceutical products; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of new products, namely, drugs and pharmaceuticals for the treatment and/or prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; research, development, and medical evaluation of pharmaceutical preparations for the prevention and treatment of cancer; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of drugs and pharmaceuticals for the treatment and/or prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, October 9, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 036 - Insurance; financial affairs; monetary affairs; real estate affairs. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, October 9, 2023 |
| Primary Code | 036 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 041 - Education; providing of training; entertainment; sporting and cultural activities. |
| US Class Codes | 100, 101, 107 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, October 9, 2023 |
| Primary Code | 041 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, October 9, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Day One Biopharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Brisbane, CA 94005 |
| Event Date | Event Description |
| Monday, October 9, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, March 8, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, March 8, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, March 8, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, June 6, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Thursday, June 6, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, September 9, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, September 9, 2024 | DIVISIONAL REQUEST RECEIVED |
| Monday, September 9, 2024 | TEAS REQUEST TO DIVIDE RECEIVED |
| Monday, September 9, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, September 10, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, September 25, 2023 | NEW APPLICATION ENTERED |
| Tuesday, February 27, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, October 10, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, October 11, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, October 15, 2024 | DIVISIONAL PROCESSING COMPLETE |
| Friday, January 10, 2025 | FINAL REFUSAL E-MAILED |
| Friday, January 10, 2025 | FINAL REFUSAL WRITTEN |
| Friday, January 10, 2025 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, January 10, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, April 9, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 9, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, April 9, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, January 10, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, January 10, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |